Translational Research Program

In the era of precision medicine, rapid translation of basic scientific discoveries to patient management has become increasingly crucial to clinical practice, particularly modern oncology. Through tissue analysis, and in collaboration with various clinical specialties, pathologists are at a unique position to interact with both basic scientists and clinical investigators to facilitate timely and efficient translation of major scientific findings to disease prevention, diagnosis, treatment and prognostication.

Armed with state-of-the-art technology, Yale Pathology has various translational subspecialty programs involving active collaborations with basic scientists and clinicians within and outside of the department. Pathology residents and subspecialty fellows are also an integral part of these academic endeavors and are encouraged to make their own contributions to translational research as part of their clinical training experience.

Translational Research Labs

In the Braddock Lab we study the pathophysiology of benign and malignant hematologic disorders using biochemical and biophysical methods.
The Kluger Lab concentrates on developing computational methodologies for analyzing high throughput biomedical data.
In the Madri Lab we investigate neural stem cell responses to injury and roles of cell-cell and cell-ECM molecules in repair.
The Min Lab has extensively employed biochemical, cell biological and mouse genetic approaches to define the critical molecules mediating vascular development, remodeling and repair related to human diseases such as vascular malformation, stroke, atherosclerosis, graft transplant rejection and tumor metastasis. We are testing small molecule, gene therapy and cell-based approaches to treat these diseases in mouse models.
The Nguyen Lab does investigation in the following areas: Metastasis; Tissue development; Lung cancer; Cancer genomics; Tumor microenvironment.
In the Politi Lab, we study mechanisms of lung tumorigenesis, in particular, the molecular features of tumors that determine response and resistance to targeted drugs.
In the Rimm Lab, we study the development and use of quantitative approaches to pathology and assay development to classify tumors or predict invasion, metastasis or response to cancer therapy
The Rose Lab focuses on developing new approaches to vaccines that will provide long-term protection against viral and bacterial diseases.
The Schalper Lab

 focuses on defining novel predictive biomarkers to identify responders and non-responders among patients who are being treated with immunotherapy for lung cancer.

The focus of the Wajapeyee Lab is to identify and characterize the regulators of tumor initiation and progression. To do so, we employ biochemical, genetic, functional genomics, pharmacological and clinical pathology-based approaches. The long-term goal is to translate our basic cancer cell biology findings into clinically effective and durable therapies for cancer treatment.
The Yan Lab studies cancer epigenetics and stem cell biology. We are interested in understanding how epigenetic aberrations cause cancer and other human diseases. In particular, we focus on the roles and regulatory mechanisms of histone demethylases from the JARID1/KDM5 protein family.